Richard Nolan Townsend - Nov 18, 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Youjin Choi, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Nov 18, 2025
Transactions value $
-$10,447
Form type
4
Date filed
11/20/2025, 05:21 PM
Previous filing
Oct 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Townsend Richard Nolan Chief Executive Officer, Director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Youjin Choi, Attorney-in-Fact 2025-11-20 0001995218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Sale -$10.4K -1.13K -0.47% $9.27 241K Nov 18, 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
F2 This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Includes 128,357 Restricted Stock Units.